What You Should Know:
– Sibel Health has recently closed a $33M Series B financing round, bringing Sibel’s total funding to date to more than $50M.
– In addition, Sibel has announced two new executive appointments. Jon Otterstatter, the former CEO and co-founder of Preventice (acquired by Boston Scientific in 2021), will join as chairman of the board. Matthew Banet, Ph.D., a world expert in advanced body-worn sensors and previously the CTO and co-founder of toSense and Sotera, joins as president from Baxter International.
Data-Driven Bio-Integrated Sensors to Promote Better Maternal and Child Health
Sibel Health is an award-winning digital health company with a mission to deliver Better Health Data for All®. Based in the greater Chicago area with offices in Seoul (South Korea) and San Diego, the company’s FDA-cleared ANNE® platform includes advanced wearable sensors, AI-enabled data analytics, and integrated mobile software and cloud platform. Sibel’s partnerships include some of the most respected healthcare organizations worldwide.
The funding round was led by the Steele Foundation for Hope—a private foundation seeking to fund solutions for humanity’s hardest challenges with an emphasis on technology and innovation. With the funding, Sibel will scale up its FDA-cleared ANNE® One platform for global deployments across the entire continuum of care from the home to the hospital.
Since 2020, Sibel has seen a significant increase in revenue driven by partnerships with leading Fortune 500 companies and funding support from the U.S. military, the National Institutes of Health, and the Bill & Melinda Gates Foundation. The appointment of new executives will accelerate Sibel’s transition to scaled commercialization.
“I look forward to joining Sibel as chairman of the board in this time of rapid acceleration and growth,” Otterstatter said. “The company’s advanced wearable monitoring platform is industry-changing—the comprehensive suite of on-body sensors, best-in-class analytics, robust machine-learning algorithms and extensible software capabilities make the ANNE® One platform a very unique offering. I look forward to supporting Sibel’s transition towards commercial scale.” He continued, “Having led a team and a company that successfully developed and achieved commercial success with a breakthrough remote cardiac monitoring solutions, I am convinced that the ANNE® sensors are raising the bar for the market.” John Rogers, PhD, the Louis Simpson and Kimberly Querrey Professor of Materials Science and Engineering at Northwestern University and Sibel co-founder, said, “It is exciting to see the research from my research group translate into a successful product with the potential to impact millions of lives worldwide, particularly in the area of neonatal and women’s health.”